S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
Free Trial
NASDAQ:ADMP

Adamis Pharmaceuticals (ADMP) Stock Price, News & Analysis

→ Uncover this 2024 Hidden Gem (From Tips4Traders) (Ad)
Free ADMP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
N/A
50-Day Range
$0.77
▼
$3.99
52-Week Range
N/A
Volume
119,800 shs
Average Volume
811,695 shs
Market Capitalization
$7.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ADMP stock logo

About Adamis Pharmaceuticals Stock (NASDAQ:ADMP)

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

ADMP Stock News Headlines

November 8, 2023 | morningstar.com
DMK Pharmaceuticals Corp DMK
September 7, 2023 | msn.com
Adamis changes name to DMK Pharmaceuticals, ticker to DMK
April 19, 2024 | DTI (Ad)
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
September 7, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals to Reflect New Strategic Focus
August 21, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 21, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 4, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Closing of $8.0 Million Public Offering
August 2, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Pricing of $8.0 Million Public Offering
April 19, 2024 | DTI (Ad)
This company has increased its dividend every year for 54 years
There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.
August 1, 2023 | msn.com
Adamis Pharmaceuticals Stock Soars To More Than Double - What's Going On?
August 1, 2023 | msn.com
Adamis stock soars as high as 480% amid asset sale, drug study news
July 28, 2023 | marketwatch.com
Adamis Pharma to Fund Clinical Study with University of Leiden Opioid Expert
July 28, 2023 | finance.yahoo.com
Adamis Pharmaceuticals to Fund ZIMHI® Clinical Study with University of Leiden Opioid Expert
June 26, 2023 | benzinga.com
Adamis Pharmaceuticals Announces NIH Grant Funding For Treatment Of Alcohol Use Disorder, Size Not Disclosed
June 26, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces NIH Grant Funding for the Treatment of Alcohol Use Disorder
June 22, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
June 4, 2023 | fool.com
Adamis Pharmaceuticals (NASDAQ: ADMP)
May 31, 2023 | benzinga.com
Adamis Pharmaceuticals CEO Awarded $210K Worth of Stock Options
May 31, 2023 | benzinga.com
Board Member at Adamis Pharmaceuticals Acquires Company Stock Options Worth 25,720 Shares
May 26, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 25, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals
May 21, 2023 | seekingalpha.com
Adamis Pharma slips 19% on plans for reverse stock slip
May 19, 2023 | finanznachrichten.de
Adamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Reverse Stock Split
May 19, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Announces Reverse Stock Split
May 16, 2023 | finance.yahoo.com
Q1 2023 Adamis Pharmaceuticals Corp Earnings Call
May 15, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 8, 2023 | finance.yahoo.com
Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update
See More Headlines
Receive ADMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2022
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:ADMP
CUSIP
N/A
CIK
887247
Web
www.adamispharmaceuticals.com
Phone
(858) 997-2400
Fax
N/A
Employees
11
Year Founded
2006

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,480,000.00
Net Margins
-502.73%
Pretax Margin
-471.80%
Return on Equity
-420.53%
Return on Assets
-256.87%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.23
Quick Ratio
0.19

Sales & Book Value

Annual Sales
$4.76 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.26) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
9,360,000
Free Float
9,237,000
Market Cap
$7.26 million
Optionable
Optionable
Beta
1.27

Social Links

7 Stocks to Own Before the 2024 Election Cover
7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David J. Marguglio (Age 53)
    Co-Founder, Interim CFO. Pres & COO
    Comp: $526.35k
  • Dr. Ebrahim Versi M.D. (Age 70)
    Ph.D., CEO & Chair of the Board
  • Ms. Jennifer C. Suski
    Sr. Director of Marketing
  • Mr. Eddie Wabern Glover (Age 73)
    Chief Exec. Officer of US Compounding Inc
  • Mr. Robert B. Rothermel (Age 79)
    Consultant

Key Competitors

View All Competitors

ADMP Stock Analysis - Frequently Asked Questions

How were Adamis Pharmaceuticals' earnings last quarter?

Adamis Pharmaceuticals Co. (NASDAQ:ADMP) announced its earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 420.53% and a negative net margin of 502.73%. During the same quarter last year, the firm earned ($11.20) earnings per share.

When did Adamis Pharmaceuticals' stock split?

Adamis Pharmaceuticals shares reverse split before market open on Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of Adamis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK).

This page (NASDAQ:ADMP) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research